摘要
目的探究注射用白蛋白结合型紫杉醇、多西他赛在乳腺癌辅助化疗中的效果与安全性。方法选取2020年7月—2023年6月于深圳市罗湖区人民医院甲乳二科进行治疗的乳腺癌患者120例作为研究对象,根据随机数表法分为两组,每组60例,两组均接受乳腺癌化疗方案,对照组增用多西他赛,研究组改用注射用白蛋白结合型紫杉醇,比对两组治疗效果。结果研究组乳腺癌疾病控制率(75.00%)高于对照组(50.00%),差异有统计学意义(χ^(2)=8.000,P<0.05)。研究组化疗后血红蛋白、白细胞减少率均高于对照组,胃肠道不良反应率低于对照组,但差异无统计学意义(P>0.05)。研究组糖类抗原125、恶性肿瘤相关物质群、癌胚抗原等水平均低于对照组,差异有统计学意义(P<0.05)。研究组疼痛评分低于对照组,差异有统计学意义(P<0.05)。结论紫杉醇+EC效果优于多西他赛,化疗后肿标水平降低。
Objective To explore the efficacy and safety of albumin-bound paclitaxel and docetaxel for injection in adjuvant Nail and Breast SurgeryⅡchemotherapy for breast cancer.Methods A total of 120 breast cancer patients who were treated in the second Department of Nail and Breast Surgery II,Luohu District People′s Hospital of Shenzhen from July 2020 to June 2023 were selected as the study objects.They were divided into two groups according to random number table method,with 60 cases in each group.Both groups received chemotherapy for breast cancer,the control group received docetaxel,and the study group used albumin-bound paclitaxel for injection,and the therapeutic effect of the two groups was compared.Results The disease control rate in the study group(75.00%)was higher than that in the control group(50.00%),and the difference was statistically significant(χ^(2)=8.000,P<0.05).After chemotherapy,the rates of hemoglobin and leukopenia in the study group were higher than those in the control group,and the rate of gastrointestinal adverse reactions was lower than that in the control group,but there was no statistical significance(P>0.05).The levels of carbohydrate antigen 125,malignant tumor related substances and carcinoembryonic antigen in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The pain score of the study group was lower than that of the control group,and the difference was statistically significant(P<0.05).Conclusion Paclitaxel+EC was more effective than docetaxel,and the swelling level was reduced after chemotherapy.
作者
叶洪珊
赵民学
司丛敏
刘姝
YE Hongshan;ZHAO Minxue;SI Congmin;LIU Shu(Department of Nail and Breast SurgeryⅡ,Luohu District People′s Hospital,Shenzhen,Guangdong Province,518001 China)
出处
《系统医学》
2023年第16期72-75,共4页
Systems Medicine
关键词
紫杉醇
多西他赛
乳腺癌
辅助化疗
效果
安全性
Paclitaxel
Docetaxel
Breast cancer
Adjuvant chemotherapy
Effect
Security
作者简介
叶洪珊(1987-),女,硕士,主治医师,研究方向为乳腺肿瘤的临床诊治;通信作者:司丛敏(9641-),男,本科,主任医师,研究方向为乳腺肿瘤的临床诊治,E-mail:andytangxys@hotmail.com。
